Blandine Lacroix is Corporate Vice President, BioPharm & Strategy
since September 1, 2020. In her role, she is responsible for managing
the U.S. Biopharmaceuticals commercial team that specializes in
treatments for people with hemophilia and other rare bleeding
disorders and growth hormone-related disorders along with leading the
U.S. organization’s enterprise strategy.
Prior to that, Ms. Lacroix led the Obesity business at Novo Nordisk
Inc. since October 2017. During that time, she was responsible for
driving strategies transforming how the world sees, prevents and
treats the disease.
Ms. Lacroix is a proven global commercial leader who brings over 20
years of experience in marketing and commercial leadership within the
pharmaceutical industry. She joined Novo Nordisk in 2002 in the
company’s Australia affiliate. Since that time, she has progressed
through roles of escalating responsibility leading global marketing
teams, at the company’s headquarters in Denmark and within the US
affiliate, across both diabetes and obesity therapeutic areas. Ms.
Lacroix led the establishment of the company’s US obesity business as
Vice President, Obesity Marketing, from 2013 to 2017.
Before joining Novo Nordisk, Ms. Lacroix managed teams and business
opportunities for several international companies across diverse
industries such as technology, health, manufacturing, and education.
Ms. Lacroix was awarded the Princeton YMCA Centennial Award for
Healthy Living, which recognizes leaders in environmental wellbeing
and sustainability, in 2017.
Ms. Lacroix studied business with a major in Finance and Accounting
as an undergraduate at the MBA Institute in Paris, France, and has a
Master of International Business from the University of South Carolina.